secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-12-06T23:59:59+00:00
Accession:  0001140361-23-056503
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GNI Japan revises FY2023 profit forecast up ¥6.97B on conversion of Gyre preferred stock
--------------------------------------------------------------------------------

- GNI Japan recognized ¥8,873M other income from converting Gyre Series X Preferred into 8,767,333 common shares.
- Revised FY2023 operating profit forecast ¥15,744M (up 116% from ¥7,280M); profit attributable to owners ¥8,971M (up 347%).
- Revised EPS forecast ¥180.42 vs previous ¥42.20; prior year ¥8.19.
- Conversion based on $0.51/share closing price of CBIO on Oct 30, 2023; shares to be issued Jan 22, 2024.
- Forecast excludes mark-to-market of Gyre common stock; further discussions ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123056503/0001140361-23-056503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123056503/ef20016120_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-056503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer